sbi-0206965 and olaparib

sbi-0206965 has been researched along with olaparib* in 1 studies

Other Studies

1 other study(ies) available for sbi-0206965 and olaparib

Article	Year
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer. Journal of medicinal chemistry, 2020, 12-10, Volume: 63, Issue:23 Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Female; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Mice, Inbred C57BL; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Triple Negative Breast Neoplasms	2020

Article

Year

Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.

Journal of medicinal chemistry, 2020, 12-10, Volume: 63, Issue:23

Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Female; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Mice, Inbred C57BL; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Triple Negative Breast Neoplasms

2020